Cardiff Oncology vs Palisade Bio
CRDF and PALI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRDF and PALI compare
Palisade Bio is the larger company, worth 2.7 times as much as Cardiff Oncology ($176M against $65.8M).
Palisade Bio keeps more of each dollar of sales as profit, with a net margin of −6388% compared with −7884% at Cardiff Oncology.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRDF | PALI |
|---|---|---|
| Size and price | ||
| Market cap | $65.8M | $176M |
| Share price | $0.846 | $1.01 |
| Change, 1 year | −60.3% | −52.8% |
| Change, 5 years | −84.9% | −99.9% |
| Beta (5Y) | 2.50 | 1.15 |
| Employees | 31 | 100K |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 130× (better) | 352× |
| P/B | 2.5× | 1.4× (better) |
| Growth | ||
| Revenue growth (TTM) | −7.0% | – |
| Revenue growth, 5Y average | 10.1% | – |
| Profitability | ||
| Operating margin | −8320% | −7070% (better) |
| Net margin | −7884% | −6388% (better) |
| Return on equity | −94.1% | −51.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −4418.6× |
| Current ratio | 3.30 | 24.26 (better) |
| Altman Z-score | −16.20 | 19.21 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −74.7% |
| Shareholder yield | 0.00% (better) | −74.7% |
| Ownership | ||
| Held by institutions | 24.2% | 99.5% |
| Held by insiders | 4.9% | 4.7% |
| Insider net buying, 12 months | $1.1M (better) | −$124K |
| Short interest, % of float | 16.6% | 17.6% |
Go deeper
- CRDF stock overview
- CRDF income statement
- CRDF valuation and score
- PALI stock overview
- PALI income statement
- PALI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.